About Neutrophil elastase
Neutrophil elastase (ELANE) is a protein
from Homo sapiens identified by UniProt accession
P08246, 267 residues long.
MolForge cross-references it against 0 known binders and
658 disease associations.
Target properties
| Protein name | Neutrophil elastase |
|---|
| UniProt accession | P08246 |
|---|
| Gene | ELANE |
|---|
| Organism | Homo sapiens |
|---|
| Length | 267 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (658)
Diseases linked to this target (Open Targets).
- neutropenia, severe congenital, 1, autosomal dominant · score 0.83
- Cyclic neutropenia · score 0.81
- cyclic hematopoiesis · score 0.81
- chronic obstructive pulmonary disease · score 0.51
- neutropenia · score 0.49
- Alpha-1-antitrypsin deficiency · score 0.49
- constitutional neutropenia · score 0.47
- severe congenital neutropenia · score 0.47
- autoinflammatory syndrome · score 0.46
- genetic disorder · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P08246-F1 | alphafold | PREDICTED | 88.20 | — |
Amino-acid sequence (267 residues)
MTLGRRLACL FLACVLPALL LGGTALASEI VGGRRARPHA WPFMVSLQLR GGHFCGATLI APNFVMSAAH CVANVNVRAV RVVLGAHNLS RREPTRQVFA VQRIFENGYD PVNLLNDIVI LQLNGSATIN ANVQVAQLPA QGRRLGNGVQ CLAMGWGLLG RNRGIASVLQ ELNVTVVTSL CRRSNVCTLV RGRQAGVCFG DSGSPLVCNG LIHGIASFVR GGCASGLYPD AFAPVAQFVN WIDSIIQRSE DNPCPHPRDP DPASRTH
Explore Neutrophil elastase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets